MindWalk Holdings (HYFT) Cash from Financing Activities (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Cash from Financing Activities of -$207909.2 for Q2 2026, up 29.22% year-over-year from -$160895.4 in Q2 2025, and up 97.83% quarter-over-quarter from -$9.6 million in Q1 2026.
MindWalk Holdings (HYFT) Cash from Financing Activities (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Cash from Financing Activities for 4 consecutive years, with -$207909.2 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Financing Activities rose 29.22% year-over-year to -$207909.2; the TTM figure through Apr 2026 stood at $81995.7 (down 99.23% YoY), while the FY2026 annual figure was $83893.2, down 99.22% from the prior year.
- Cash from Financing Activities rose to -$207909.2 in Q2 2026 per HYFT's latest filing, from -$9.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $10.1 million in Q4 2025 and bottomed at -$9.6 million in Q1 2026.
- Historically, Cash from Financing Activities has averaged $782867.9 across 4 years, with a median of -$208491.2 in 2023.
- Annual changes were most pronounced in 2025 — Cash from Financing Activities jumped 1538.31% — and 2026, when it slumped 229.06%.
- MindWalk Holdings' Cash from Financing Activities stood at -$228623.1 in 2023, then soared by 762.71% to $1.5 million in 2024, then soared by 569.78% to $10.1 million in 2025, then sank by 102.05% to -$207909.2 in 2026.
- Business Quant data shows HYFT's Cash from Financing Activities at -$207909.2 in Q2 2026, -$9.6 million in Q1 2026, and $10.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -181.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -207,909.22 |
| Apr 30, 2026 | -207,909.22 |
| Jan 31, 2026 | -9.59 Mn |
| Jan 31, 2026 | -9.59 Mn |
| Oct 31, 2025 | 10.15 Mn |
| Oct 31, 2025 | 10.15 Mn |
| Jul 31, 2025 | -270,008.36 |
| Jul 31, 2025 | -270,008.36 |
| Apr 30, 2025 | -293,740.59 |
| Apr 30, 2025 | -293,740.59 |
| Jan 31, 2025 | 7.43 Mn |
| Jan 31, 2025 | 7.43 Mn |
| Oct 31, 2024 | 1.52 Mn |
| Oct 31, 2024 | 1.52 Mn |
| Jul 31, 2024 | 1.97 Mn |
| Jul 31, 2024 | 1.97 Mn |
| Apr 30, 2024 | 828,235.27 |
| Apr 30, 2024 | 828,235.27 |
| Jan 31, 2024 | 453,449.27 |
| Jan 31, 2024 | 453,449.27 |